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seems to be required for normal muscle development, but only during
earlier ages than those studied here (Madaro et al., 2012). Diaphragm
and cardiacmuscles are importantmuscles to be studied under a clinical
point of view, with the diaphragm being the most affected muscle in
mdx. Considering the cardiac muscle, C20 did not induce fibrosis in the
normal heart and did not change the expression of TGFβ, a pro-fibroticDuchennemuscular dystrophy (DMD) is an X-linkedmuscle disease
affecting approximately 1 in 3600–6000 live male births (Mendell et al.,
2012) characterized by the lack of dystrophin, progressive skeletalmus-
cle degeneration and cardiorespiratory failure. Although DMD is one of
the best studied muscle disorders, no cure is still available. Gene re-
placement therapy constitutes the best hope for treating DMD. Howev-
er, gene therapies are still under development (Muntoni et al., 2016)
and the only medication so far able to retard the progression of DMD
are corticoids. (Matthews et al., 2016)
Lack of dystrophin is the primary defect in DMD. In the absence of
dystrophin, there is sarcolemma instability, increased calcium influx
andmyonecrosis (Deconinck andDan, 2007). Cycles ofmuscle degener-
ation-regeneration promotes a chronic inflammation, which is a sec-
ondary event that further contributes to the pathogenesis of
dystrophy (Villalta et al., 2009). The beneficial effects of corticoids are
to reduce inflammation. However, the secondary adverse effects of cor-
ticoids stimulate the search for new drugs. In this scenario, the impor-
tance of the report made by Marrocco and colleagues (Marrocco et al.,
2017) is that they offer evidence for a new potential therapy to DMD,
by testing a specific inhibitor of protein kinase C theta, named com-
pound 20 (C20), in themdxmice model of DMD.
Previously, it had been shown that ablation of protein kinase C (PKC)
theta ameliorated mdx dystrophy (Madaro et al., 2012). In the present
study, Marrocco and colleagues (Marrocco et al., 2017) showed that
C20 prevented T cell activation by concanavalin A, in peripheral T cells
in wild-type mice, thus demonstrating the inhibitory activity of C20
on PKC theta, which is an essential factor to promote T cell activation.
In the dystrophic gastrocnemius, C20 reduced myofiber degeneration
(IgG-positive fibers were decreased), inflammation (decrease the levels
of NF-kB and of CD45-positive cells) and improved regeneration. These
results suggest that C20 was able to ameliorate a limb dystrophicom.2017.01.001.
. This is an open access article undermuscle, at an early stage of dystrophy. Interesting, PKC theta activity
factor, in the 4 week-old wildtype mice (Marrocco et al., 2017). In the
mdx mouse, cardiac changes, such as fibrosis and ECG abnormalities,
are first seen in aged mdx mice (Bostick et al., 2008). Therefore, it
would be interesting to investigate the effects of C20 at later stages of
the disease, to verify whether C20 therapy could also counteract fibrosis
formation in diaphragm and heart, since fibrosis is responsible for the
functional loss of skeletal and cardiac muscles, in DMD.
An intriguing finding of the present study was the observation that
C20 leads to an increase in tibialis anterior muscle mass that seemed
to result from an increase in the number of myofibers, in the wildtype
mice. This is a very interesting finding, deserving further studies about
the mechanisms involved. Increasing the number of muscle fibers
points out for the potential effects of C20 on satellite cells, considered
the stem cells of skeletal muscles. Due to the cycles of degeneration
and regeneration, there is exhaustion of the satellite cell pool and de-
fects inmuscular regeneration. Notch andWnt pathways, which are in-
volved in satellite cell renewal and myogenesis, seem to be impaired in
dystrophy (Jiang et al., 2014) and whether PKC theta signaling is in-
volved in these pathways remains to be elucidated.
The functional evaluations performed in this study need to be
highlighted. Treadmill protocols are useful to exacerbate muscle dam-
age in the dystrophic muscle, due to contraction-induced injury related
to running, and arewidely used in proof-of-concept studies to verify the
benefits of pre-clinical drugs in vivo (Radley-Crabb et al., 2012). They
performed ex vivo analysis of limb muscle contraction force (C20
prevented loss of EDL muscle force) and in the treadmill exercise, they
verified that C20-treated mdx performed better than the untreated
mdx, running longer distances and taking more time to reach exhaus-
tion. The better functional performancewas accompanied by amorpho-
logical improvement in both gastrocnemius and, very important, in the
diaphragmmuscle due to C20 therapy, as demonstrated by a significant
decreased in IgG-positive fibers, an indicative of myonecrosis.
While PKC theta inhibition and C20 emerge as a potential new ther-
apeutic approach to be tested in future clinical trials in DMD patients,
wemust be careful when extrapolating data frommice to humans. Sev-
eral aspects still to be investigated include dosage, toxicity, long-termthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
15M.J. Marques / EBioMedicine 16 (2017) 14–15therapy, and the effects of the combination corticoid and PKC theta inhi-
bition to the patients that are already under corticoid therapy. Another
important issue to highlight for future work would be the characteriza-
tion of the PKC theta -dependent immune response, sinceMarrocco and
colleagues (Marrocco et al., 2017) only showed reduction of CD45-
positive cells, but the major players in these events are still elusive,
and how PKC theta inhibitionmaymodulate immune response remains
unknown. Overall, Marrocco and colleagues (Marrocco et al., 2017)
work opens new perspectives in the management of muscular diseases
and in the molecular pathways involved in muscle regeneration and
inflammation.
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